Protein detoxification

History

In 1970, it was demonstrated that protein turnover releases the free methylated arginine derivatives:

1. asymmetric dimethylarginine (ADMA),
2. methylarginine, (also referred to as N-methyl-L-arginine, N-monomethylargine or L-NMMA), and
3. symmetrical dimethylarginine (SDMA).

The potential toxicity of the two asymmetrically methylated amino acids however was not fully appreciated until 1992 when Patrick Vallance and his London co-workers at the Wellcome Research Laboratories demonstrated that ADMA inhibits nitric oxide synthase (NOS). Then, in 1996 MacAllister at St George's Hospital Medical School in London, recognised that inhibiting the enzyme DDAH increases intracellular concentrations of ADMA. To describe the process of protein turnover, the elimination of free methylated arginine derivatives and the catabolism of the two asymmetrically methylated arginine derivatives ADMA and L-NMMA, the Australian physician Trevor Tingate coined the term protein detoxification in 2010.

Synthesis and clearance

Protein arginine methylation occurs posttranslationally and is catalysed by protein arginine methyltransferase (PRMT). No direct synthesis of methylated arginine derivatives occurs from the free amino acid. The methylation of protein arginine plays an important role in the regulation of many cell processes including gene transcription, cell signal transduction, DNA repair and RNA processing.

During protein turnover three arginine methylated derivatives are released: L-NMMA, SDMA and ADMA. :SDMA is not directly toxic and is eliminated unchanged by renal excretion. :L-NMMA and ADMA however, are both potent inhibitors of NOS.

Around 60 mg of ADMA is produced per day. Unlike SDMA, 80% of ADMA and NMMA is catabolised by the enzyme DDAH. The activity of DDAH is therefore an important determinant of ADMA and NMMA levels, and thus NOS activity.

File:PDB_1orh_EBI.jpg|Protein arginine N-methyltransferase 1 (PRMT1) File:PDB_1h70_EBI.jpg|Dimethylarginine dimethylaminohydrolase (DDAH) File:Asymmetric dimethylarginine.svg|Asymmetric dimethylarginine (ADMA) File:N-Methyl-D-arginine.png|N-methyl-L-arginine (L-NMMA)

PRMTs

Protein arginine methyltransferase's (PRMTs) are activated by shear stress and LDL cholesterol. Two types of PMRTs have been characterised. :Type 1 PRMTs are found mainly in endothelial and smooth muscle cells and produce methylated proteins containing ADMA and L-NMMA. :Type 2 PRMTs produce proteins that contain SDMA and L-NMMA.

DDAH

Dimethylarginine dimethylaminohydrolase (DDAH) activity is inhibited by NO, reactive oxygen species (ROS) and L-arginine.

Two isoforms of DDAH have been identified. :DDAH-1 is found in tissues expressing neuronal NOS (nNOS) and in the liver, kidney and lung. Expression is increased by IL-1β and inhibited by oxLDL and TNF. Plasma levels of ADMA reflect DDAH-1 activity.

:DDAH-2 is found in tissues expressing endothelial NOS (eNOS) and inducible NOS (iNOS). Expression is increased by NADPHox, all trans retinoic acid, pioglitazone and estradiol and inhibited by hypoxia, hyperglycaemia and LPS.

Role in disease

Asymmetrically methylated arginine forms (AMAF) inhibit nitric oxide synthase and the formation of nitric oxide (NO), also known as 'endothelium-derived relaxing factor', or 'EDRF'. Nitric oxide is critical to blood vessel function and inhibition leads to an increase in arterial stiffness due to vasoconstriction. Indeed, by protecting the vessel against vasoconstriction nitric oxide has been referred to as the fountain of youth. It also protects blood vessels by inhibiting platelet activation, smooth muscle proliferation and endothelial cell activation.

Reduced arterial stiffness protects the heart. Asymmetrically methylated arginine forms by contrast inhibit NOS, reduce nitric oxide and increase central arterial pressure.

Long-standing arterial stiffness inevitably leads to heart failure, kidney failure and dementia; the three leading causes of death in later years. Protein detoxification removes free methylarginines that would otherwise inhibit the generation of nitric oxide. The pathway is an important determinant of the speed by which diseases of ageing will ultimately manifest.

Aging

When William Osler stated that “man is as old as his arteries” he referred to arterial stiffening, a condition now acknowledged as an integrated biomarker of ageing.

Preservation of the arterial tree in a relaxed and elastic state is core doctrum of anti-ageing medicine. The recognition of free methylarginine derivatives as toxins that accelerate ageing by inhibiting the production of nitric oxide focuses on the importance of maintaining the protein detoxification pathway.

This can be achieved by a combination of dietary, behavioural and therapeutic interventions.

References

References

1. Ito, A. [http://circ.ahajournals.org/cgi/reprint/99/24/3092 Novel Mechanism for Endothelial Dysfunction: Dysregulation of Dimethylarginine Dimethylaminohydrolase] Circulation 1999;99;3092-3095
2. Boger, R. [https://web.archive.org/web/20110205170332/http://cardiovascres.oxfordjournals.org/content/59/4/824.full.pdf+html The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor] Cardiovascular Research 2003;59:824–833
3. Palm, F. [http://ajpheart.physiology.org/cgi/reprint/293/6/H3227 Dimethylarginine dimethylaminohydrolase (DDAH): expression, regulation, and function in the cardiovascular and renal systems] Am J Physiol Heart Circ Physiol 2007;293:H3227–H3245
4. Kielstein, J. [http://www.kielstein.com/adma/G2005AJKD.pdf Asymmetric Dimethylarginine: A Cardiovascular Risk Factor and a Uremic Toxin Coming of Age?] {{webarchive. link. (2011-07-13 Am J Kidney Dis. 2005;46:186-202)
5. Kakimoto, Y. [http://www.jbc.org/content/245/21/5751.full.pdf+html Isolation and identification of N,N and N,N-Dimethyl-arginine, N-mono-, and Trimethyllysine, and Glucosylgalactosyl-, and Galactosyl-δ-hydroxylysine from human urine] J Biol Chem 1970;245: 5751-5758
6. Vallance, P. [https://www.ncbi.nlm.nih.gov/pubmed/1347093 Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure] Lancet 1992;339(8793):572-5
7. MacAllister, R. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1915783/pdf/brjpharm00077-0035.pdf Regulation of nitric oxide synthesis by dimethylarginine dimethylaminohydrolase] Br J Pharmacol 1996;119(8):1533-40
8. Bedford, M. [http://www.biologia.uniba.it/dbbm/Kanduc/Arginine%20Methylation%20-%20Review.pdf Arginine Methylation: Review: An Emerging Regulator of Protein Function] {{webarchive. link. (2011-07-21 Molecular Cell 2005;18:263–272)
9. Masuda, H. [http://ajpregu.physiology.org/cgi/reprint/282/6/R1730 Accumulated endogenous NOS inhibitors, decreased NOS activity, and impaired cavernosal relaxation with ischemia] Am J Physiol Regulatory Integrative Comp Physiol 282: R1730–R1738, 2002
10. Achan, V. [http://atvb.ahajournals.org/cgi/reprint/23/8/1455.pdf Asymmetric Dimethylarginine Causes Hypertension and Cardiac Dysfunction in Humans and Is Actively Metabolized by Dimethylarginine Dimethylaminohydrolase] Arterioscler Thromb Vasc Biol 2003;23:1455-1459
11. Cooke, P. [http://vmj.sagepub.com/cgi/reprint/15/3/235 DDAH: A target for vascular therapy?] Vasc Med 2010;15;235-238
12. Osanai, T. [http://hyper.ahajournals.org/cgi/reprint/42/5/985 Effect of Shear Stress on Asymmetric Dimethylarginine Release From Vascular Endothelial Cells] Hypertension 2003;42:985–90
13. Böger, R. [http://circres.ahajournals.org/cgi/reprint/87/2/99 LDL Cholesterol Upregulates Synthesis of Asymmetrical Dimethylarginine in Human Endothelial Cells] Circ Res 2000;87:99–105
14. Anthony, S. [http://vmj.sagepub.com/cgi/reprint/10/2_suppl/S3 Endogenous production of nitric oxide synthase inhibitors] Vascular Medicine 2005; 10: S3–9
15. Palm, F. [http://ajpheart.physiology.org/cgi/reprint/293/6/H3227 Dimethylarginine dimethylaminohydrolase (DDAH): expression, regulation, and function in the cardiovascular and renal systems] AJP Heart Circ Physiol 2007;293:H3227–H3245
16. Blackwell, S. [http://acb.rsmjournals.com/cgi/content/abstract/47/1/17 The biochemistry, measurement and current clinical significance of asymmetric dimethylarginine] Ann Clin Biochem 2010;47:17–28
17. Zakrzewicz, D. [http://www.biomedcentral.com/content/pdf/1471-2466-9-5.pdf From arginine methylation to ADMA: A novel mechanism with therapeutic potential in chronic lung diseases] Pulmonary Medicine 2009;9:1471-2466
18. Osler, W. [http://www.medicalarchives.jhmi.edu/osler/PrinciplesandPractice.htm The Principles and Practice of Medicine. 3rd edition. New York, NY: Appleton] 1892